on, including its quarterly report on Form 10-Q filed
today with the SEC. You are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date of this
release. Medivation disclaims any obligation or undertaking to update or
revise any forward-looking statements contained in this press release.
~financial statements to follow~
MEDIVATION, INC.
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
Period from
Inception
Three Months Ended Nine Months Ended (September 4, 2003)
September 30, September 30, to
2008 2007 2008 2007 September 30, 2008
Operating
expenses:
Research
and
develop-
ment $15,514 $6,797 $41,728 $16,306 $84,067
General
and
admin-
istrative 5,122 3,026 13,532 7,383 32,694
Total
operating
expenses 20,636 9,823 55,260 23,689 116,761
Loss from
operations (20,636) (9,823) (55,260) (23,689) (116,761)
Other income
(expense):
Interest
income,
net 170 460 735 1,522 3,674
Other
income
(expense),
net 10 - (4) (3) (1,642)
Total
other
income
(expense) 180 460 731 1,519 2,032
Net loss $(20,456) $(9,36
'/>"/>
SOURCE Medivation, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 20082.
Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer3.
Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients4.
Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America5.
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon6.
Medivation Announces Participation in Upcoming Conferences7.
Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update8.
Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 20089.
Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 510.
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients11.
Medivation Announces Senior Management Promotions